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INTRODUCTION
In veterinary oncology the use of the cytotoxic drug
1-(2-chloro-ethyl)-3-cyclohexyl-1-nitrosourea (lo-
mustine) is on the rise. In human oncology, the major
indications for the use of lomustine are primary and
metastatic brain tumors in patients who have already
received appropriate surgery and/or radiotherapy or as
a palliative treatment (Parney and Chang, 2003). Lo-
mustine is indicated as secondary treatment in combi-
nation with other approved drugs in patients with
relapsed or primary therapy resistant Hodgkin’s or
non-Hodgkin lymphoma (Stuart et al., 2001; Musolino
et al., 2005; Alexandrescu et al., 2006) and in cases of
melanoma skin metastasis (Lens and Eisen, 2003). The
major indication in veterinary medicine for the use of
this drug is the treatment of canine lymphoma patients,
either during the protocols used to achieve a first re-
mission in the different subtypes of T-cell lymphomas
or as a rescue agent in relapsed T-and B cell lymphoma
(Risbon et al., 2006; Williams et al., 2006; Saba et al.,
2007; Sauerbrey et al., 2007). Also in dogs with mast
cell tumors (Rassnick et al., 1999), brain tumors (Van
Meervenne et al., 2007) and histiocytic proliferative
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ABSTRACT
In veterinary oncology the use of the nitrosourea compound lomustine is increasing. Veterinary oncolo-
gists need to be aware of the pulmonary toxicity of this drug. 
Because of the lack of veterinary publications on this subject, the incidence and pathophysiology in human
cancer patients of pulmonary toxicity induced by cytotoxic agents in general and by nitrosoureas in particu-
lar are discussed. Three clinical syndromes can be recognized, the most devastating of which is interstitial
pneumonitis resulting in pulmonary fibrosis. Disturbances in the homeostatic mechanisms of the oxidant/anti-
oxidant-, immunologic-, matrix repair-, proteolytic-, and central nervous systems are some of the major mecha-
nisms of pulmonary injury in human medicine. Risk factors such as cumulative dose, age, radiation, oxygen
administration and multi-drug regimens are recognized. 
For the first time in veterinary medicine, a case report of a dog with pulmonary fibrosis, probably caused
by chronic lomustine administration, is presented. 
SAMENVATTING
Het gebruik van lomustine, behorende tot de nitrosourea’s, neemt toe in de veterinaire oncologie. Dierenartsen
dienen zich bewust te zijn van de longtoxiciteit van dit medicijn.
Door het gebrek aan diergeneeskundige bronnen worden het voorkomen en de pathofysiologie van de longtoxi-
citeit bij humane kankerpatiënten, veroorzaakt door cytostatica in het algemeen en door nitrosourea’s in het bijzon-
der, besproken. Drie klinische syndromen worden beschreven, waarvan interstitiële pneumonie resulterend in
longfibrose de meeste consequenties voor de patiënt heeft. De verstoring van de homeostase van de oxidant/antioxi-
dant-, immunologische, ‘matrix repair’- en proteolytische systemen en het centrale zenuwstelsel zijn verant-
woordelijk voor de longschade bij humane patiënten. Risicofactoren, zoals cumulatieve dosis, leeftijd, bestraling,
zuurstoftoediening en multidrugprotocollen worden vermeld. 
Voor het eerst in de diergeneeskunde wordt een case report van een hond met longfibrose, die waarschijnlijk
veroorzaakt is door een langdurig lomustinegebruik, beschreven.
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lesions (Skorupski et al., 2007), lomustine shows
promising results.
The side effects of lomustine in human oncology
are transient leucopenia, cumulative thrombocytope-
nia, hepatic and renal toxicity and pulmonary toxicity
resulting in lung fibrosis (Schacht et al., 1981; Vats et
al., 1982; Wakui, 1982; Stone and Richardson, 1987;
Marquette et al., 1992; Stonich and Bressler, 1998). In
veterinary medicine, especially leucopenia, cumula-
tive thrombocytopenia and hepatic toxicity are re-
ported (Rassnick et al., 1999; Fan and Kitchell, 2000;
Kristal et al., 2004; Sauerbrey et al., 2007). Since
little is known about the pulmonary toxic side effects
of lomustine in veterinary oncology, the purpose of
this article is to discuss comparative aspects, and to
present a case report of lung fibrosis in a dog, most
likely induced by lomustine. Awareness of, and alert-
ness to this toxicity and its relative risk is important
for veterinary clinical oncologists. Early recognition
of this problem and withdrawal of the injurious agent
is the best treatment. With an improved understanding
of how agents like lomustine damage lung tissue,
vete rinary clinicians may be able to administer these
drugs to their patients, while still preventing or delay-
ing pulmonary toxicity.
GENERAL COMPARATIVE AND PHARMACO-
LOGICAL ASPECTS
One of the side effects of medical treatment of neo-
plastic disease is damage to the vulnerable tissues of
the pulmonary system. Diffuse pulmonary diseases
seen in human patients receiving chemotherapy have a
wide variety of etiologies, including infection,
involvement with the underlying disease, injury from
diag nostic agents or radiation, and toxicity from
chemotherapeutic drugs (Klein and Wilds, 1983;
Cooper et al., 1986; Dweik and Ahmad, 1998; Camus
et al., 2001; Foucher and Camus, 2001; Ozkan et al.,
2001; Evans and Limper, 2006). 
The chemotherapeutic agents currently known to
cause pulmonary toxic side effects in humans, usually
manifested as interstitial pneumonitis, alveolitis and
ultimately pulmonary fibrosis, are considerably greater
in number than may be generally appreciated by clini-
cians. Bleomycin, busulfan, methotrexate, carmustine,
lomustine, semustine, zinostatin, mitomycin, procar-
bazin and chlorambucil are agents known to cause
these problems. Methotrexate, lomustine, procarbazine
and chlorambucil are also used in veterinary medicine
in cumulative dosages (Weiss and Muggia, 1980;
Weiss et al., 1981; Klein and Wilds, 1983; Cooper et
al., 1986; Twohig and Matthay, 1990; Dweik and
Ahmad, 1998; Camus et al., 2001; Ozkan et al., 2001;
Evans and Limper, 2006). The appearance of pul-
monary fibrosis secondary to antineoplastic therapy
may be insidious in onset and progress to a fatal out-
come (Klein and Wilds, 1983). 
Clinical features are similar for most categories of
cytotoxic agents. However, treatment and outcome
vary with each particular agent (Klein and Wilds,
1983; Cooper et al., 1986).
Interaction between these drugs and thoracic radiation
or high oxygen fractions in inspired air has produced
pneumonitis at doses lower than when a drug is used
alone. Synergism between the drugs themselves, when
given concurrently, is believed to produce pulmonary
toxicity at lower doses (Weiss and Muggia, 1980;
Klein and Wilds, 1983; Stonich and Bressler, 1998;
Camus et al., 2001; Evans and Limper, 2006). 
Within the group of pulmonary toxicities induced
by cytotoxic drugs in general, lung injury by ni-
trosoureas has emerged as a significant problem in
human oncology (Hundley and Lukens, 1979; Weiss
et al., 1981; Smith, 1989; Massin et al., 1992;
O’Driscoll, 2000). Nitrosoureas belong to the group of
alkylating agents and include carmustine (BCNU), lo-
mustine (CCNU) and semustine (methyl-CCNU). Ni-
trosoureas are highly lipophilic compounds that
undergo hydrolysis in the liver by the hepatic micro-
somal enzyme oxidation system to form reactive
metabolites. These metabolites cause alkylation and
cross-linking of DNA. Other biologic effects include
inhibition of DNA synthesis and some cell cycle phase
specificity. Nitrosoureas generally lack cross-resis-
tance with other alkylating agents. While it is difficult
to ascertain the exact prevalence of nitrosoureas in-
duced lung pathologies, it is now clear that a direct re-
lationship exists between cumulated exposure to a
nitrosourea and the likelihood of developing pul-
monary toxicity (Schabel, 1976; Wakui, 1982). 
Carmustine is the most widely used nitrosourea
compound in human oncology and is associated with
a high risk of pulmonary toxicity. Symptoms may
begin as early as one month and as late as one year
after initiation of treatment (Klein and Wilds, 1983).
Up to 25% of patients receiving carmustine develop
early-onset pulmonary fibrosis within 36 months after
start of therapy. Lung fibrosis is especially likely to
occur with cumulative doses of carmustine over 1500
mg/m2 (Ozkan et al., 2001). However, one study of 94
Hodgkin’s lymphoma patients receiving carmustine re-
ported early-onset interstitial pneumonitis in up to
47% of the patients whose cumulative doses were
more than 535 mg/m2 and 26% of these patients died,
whereas 15% developed toxicity at doses lower than
475 mg/m2. Statistical analysis revealed that the only
independent variables associated with lung disease
were total dose of carmustine and female sex (Phillips
and Reece, 1986). Carmustine may also cause a late-
presenting form of lung fibrosis, which has been re-
ported in survivors of childhood brain tumors. In one
study, after 16 to 20 years of follow-up, 8 of 17 pa-
tients died of pulmonary fibrosis. Some patients may
be asymptomatic for many years and become sympto-
matic at any time (O’Driscoll, 2000; Mertens et al.,
2002). 
Semustine and lomustine are less frequently re-
ported to be toxic to the lungs. Onset of toxicity after
use of semustine and lomustine has occurred after an
interval of 6 months or longer from the start of therapy.
Usually toxicity occurs with a cumulative dose of lo-
mustine over 1100 mg/m2 (Lee et al., 1978; Dent,
1982 ; Vats et al., 1982 ; Cordonnier et al., 1983 ;
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Tucci et al., 1986 ; Stone and Richardson, 1987; Block
et al., 1990 ; Marquette et al., 1992). There is one re-
port of pulmonary toxicity after semustine use at a cu-
mulative dose of only 600 mg/m2 (Block et al., 1990).
At present, only lomustine is of significance for clini-
cal use in veterinary oncology. Carmustine has been
used in veterinary medicine for the treatment of brain
tumors and lymphoma, though with several disadvan-
tages. The drug is not easily available, it is expensive
and it has to be slowly administered intravenously.
Gastro-intestinal complaints, delayed and cumulative
bone marrow suppression and lethargy were frequently
encountered side effects (Merker et al., 1975; Lucas et
al., 2004). 
To the author’s knowledge, no case of pulmonary
fibrosis associated with lomustine treatment has been
reported.
CLINICAL SYNDROMES IN HUMAN CANCER
PATIENTS
While much of the pathophysiology of toxic lung
injury from specific agents is unknown, three common
clinical-pathologic syndromes have been associated
with chemotherapy induced lung injury: interstitial
pneumonitis followed by fibrosis, hypersensitivity
pneumonitis, and an acute pneumonitis with non-car-
diogenic pulmonary edema. Drug-induced interstitial
pneumonitis can lead to permanent damage through fi-
brosis, whereas hypersensitivity pneumonitis and non-
cardiogenic pulmonary edema are usually reversible.
Some human patients will present with symptoms
from more than one syndrome, and some drugs can
cause more than one type of toxicity (Klein and Wilds,
1983; Stonich and Bressler, 1998; Ozkan et al., 2001;
Evans and Limper, 2006).
Interstitial pneumonitis progressing to pulmonary
fibrosis has a clinical picture which is remarkably con-
sistent for pulmonary toxicity attributable to the spec-
trum of antineoplastic agents. However, it should be
noted that it is rarely associated with the antimetabo-
lites, such as methotrexate. The patients experience
slow, progressive (i.e. weeks to months) dyspnea on
physical exertion, a non-productive cough, fever,
weight loss and fatigue. The development of these
symptoms generally precedes the appearance of
radiographic changes. The radiographic findings are
reticular infiltrates starting in the sub-pleural region of
the lung bases and progressing to include the entire
lung. Based on clinical utility and assessment of
severity, the antineoplastic drug may be discontinued
in an attempt to manage this toxicity. Steroids have
been administered to enhance resolution of this syn-
drome, but documentation of their efficacy is anec-
dotal. Usually, the outcome is poor, with most of the
patients dying. Lung transplant offers the best hope of
long-term survival (Klein and Wilds, 1983; Massin et
al., 1992; Stonich and Bressler, 1998; Ozkan et al.,
2001).
Hypersensitivity pneumonitis is commonly associa-
ted with bleomycin, methotrexate and procarbazine,
and is manifested as an acute syndrome (i.e. hours to
days) consisting of dyspnea, fever and non-productive
cough. Peripheral and/or pulmonary eosinophilia can
be observed. Chest radiographs show localized or bi-
lateral alveolar infiltrates. Standard treatment of these
hypersensitivity reactions includes drug discontinua-
tion and steroid administration, resulting in a good
prognosis for the affected patient (Klein and Wilds,
1983; Stonich and Bressler, 1998; Ozkan et al., 2001;
Evans and Limper, 2006).
Non-cardiogenic pulmonary edema has a pattern of
pulmonary toxicity which is very rare. It is reported as
an acute complication in association with the use of
cytarabine, methotrexate and cyclophosphamide. Pa-
tients are presented in acute respiratory distress oc-
curring over several hours. Chest radiographs show
diffuse ill-defined acinar infiltrates and normal heart
size. The prognosis is variable and no validated
therapy is available for this group of patients (Klein
and Wilds, 1983; Stonich and Bressler, 1998; Ozkan
et al., 2001; Evans and Limper, 2006).
MECHANISMS OF PULMONARY INJURY
Pulmonary toxicity secondary to antineoplastic
drugs may be due to a variety of mechanisms. There
are five major postulated mechanisms in human
medicine to explain the development of this toxicity,
each of which can cause pulmonary injury either as a
single mechanism or in combination with any of the
other four. Generally it is thought that antineoplastic
agents induce pulmonary injury by disturbing
homeostatic mechanisms. An imbalance between
inflammatory reactions that may cause pulmonary
damage and protective detoxification reactions can
occur for the following systems:
Oxidant/antioxidant system
Lung tissue and the alveolar epithelial lining fluid
contain high levels of antioxidants that presumably
protect against oxidants and/or free radicals. Cytotoxic
drugs can trigger the formation of reactive oxygen
metabolites such as superoxide anions, hydrogen
peroxide, and hydroxyl- and carbonate radicals. These
oxidant molecules, formed within phagocytic cells
such as monocytes, macrophages and neutrophils, can
result in direct injury to the lungs. They can also initi-
ate a metabolic cascade that produces immuno-
reactive substances like prostaglandins and other cyto -
kines, which in turn lead to inflammation and lung
damage. The toxic effects of the free radicals may
compromise the production of lung surfactant and
damage the delicate alveolar structures, resulting in
histopathologic changes that may progress to fibrosis.
They also may participate in redox reactions resulting
in fatty acid oxidation that can lead to membrane in-
stability and perhaps autologous cytotoxicity (Klein
and Wilds, 1983; Stonich and Bressler, 1998;
Abushamaa et al., 2002). 
Normally, antioxidant defense mechanisms such as
the production of superoxide dismutase, glutathione
peroxidase, and alpha-tocopherol provide the neces-
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sary balance to compensate for the noxious oxidant ef-
fects. When antineoplastic drugs are administered,
there may be a disturbance of this homeostasis result-
ing in pulmonary injury (Klein and Wilds, 1983;
Stonich and Bressler, 1998; Abushamaa et al., 2002). 
Theoretically, the production of these highly oxi-
dizing radicals might be increased by the inspiration
of high concentrations of oxygen, for example
delivered during oxygen therapy and anesthesia pro-
tocols. Also, ionizing thoracic radiotherapy may cause
additive toxic effects by the additional production of
free radicals (Klein and Wilds, 1983; Stonich and
Bressler, 1998). 
Immunologic system
Even in the healthy state, pulmonary host cells can
exaggerate toxic reactions caused by exposure to sub-
stances that initiate or activate the immunologic sys-
tem. Pulmonary cells release mediators (e.g.
cytokines) that attract and activate inflammatory cell
types like eosinophils, monocytes and neutrophils. To
counterbalance the amplified effects of the immuno-
logic system that may result in pulmonary tissue da -
mage, tolerant cells exist, such as  lymphocytes and
alveolar macrophages. It is postulated that when cyto-
toxic drugs are administered, there is a disturbance of
this homeostasis of toxic reaction and tolerant sup-
pressor cells. This may be a result of different kinds of
immunologic mechanisms, such as hypersensitivity
reactions, leading to pulmonary injury and, in some
patients, finally to pulmonary fibrosis. Eosinophilia
has been reported with procarbazine- and methotrexate-
induced pulmonary toxicity. Steroid responsiveness
suggests the possibility of this immunologic mecha-
nism (Klein and Wilds, 1983; Stonich and Bressler,
1998).
Matrix repair system
Normally, the proliferation of fibroblasts leading to
collagen deposition is helpful in repairing or limiting
tissue injury. However, excessive deposition of colla-
gen can result in organ structure impairment. Cyto-
toxic drugs can alter this balance between collagen
formation and collagenolysis, resulting in fibrosis
through modulation of fibroblast proliferation and/or
excessive collagen deposition (Stonich and Bressler,
1998).
Proteolytic system
Inflammatory cells produce a number of proteolytic
enzymes that are associated with many pulmonary dis-
turbances. Proteolytic enzymes are normally con-
trolled or inactivated by protease inhibitors that are
mediated by oxidant molecules. It is thought that al-
though antineoplastic drug parent molecules do not af-
fect this homeostasis, their oxidant radicals may
inactivate protease inhibitors, thereby allowing proteo-
 lytic enzymes to function unopposed (Stonich and
Bressler, 1998).
Central nervous system
The central nervous system provides some control
over pulmonary capillary permeability, for example by
influencing the isoprenoid pathway. Dysfunction of
this pathway, through an increase of endogenous
digoxine in the hypothalamus, contributes to the patho-
genesis of idiopathic pulmonary fibrosis in humans
(Kurup and Kurup, 2003). It has been postulated that
cytotoxic drugs may influence the hypothalamus and
medulla in such a way that pulmonary capillary per-
meability is increased (Stonich and Bressler, 1998).
However, a direct relation between the dysfunction of
this pathway and the chronic use of cytotoxic agents
has not yet been proven. 
RISK FACTORS FOR THE DEVELOPMENT OF
PULMONARY TOXICITY IN HUMANS
As has been discussed, antineoplastic drugs do in-
duce pulmonary toxicity. However, it should be con-
sidered that not all patients receiving these agents
experience this toxicity. To identify those patients at
risk, five major predisposing factors for the develop-
ment of pulmonary toxicity are noted, together with
some predisposing factors of minor importance. 
Cumulative dose
Cytotoxic agents that are directly toxic to the lungs
generally exhibit increasing toxicity with increasing
dose. This is believed to be a result of drug accumula-
tion in the lung itself. Two patterns of dose related pul-
monary toxicity have been clinically observed
(Stonich and Bressler, 1998).
A threshold effect, where there is a marked increase
in pulmonary toxicity beyond a specific amount of
drug received.
A linear effect, where there is a constantly in-
creasing risk for the development of pulmonary
toxicity, directly related to the amount of drug
administered (e.g. lomustine) (Massin et al., 1992). 
Age
A normal physiologic phenomenon that has been
observed with aging is a decrease in the effectiveness
of the antioxidant defense system. Accordingly, as they
age, patients become more susceptible to pulmonary
toxicity induced by cytotoxic drugs. However,
increased age has been shown to be a risk factor only
for the development of bleomycin-induced pulmonary
disease (Stonich and Bressler, 1998).
Radiation
Radiation therapy results in the production of oxi-
dant products that may lead to pulmonary damage.
When antineoplastic agents, which also affect the
oxidant/antioxidant homeostasis, are administered,
there may be synergistic pulmonary toxicity (Klein
and Wilds, 1983; Stonich and Bressler, 1998). 
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Oxygen administration
Reactive oxidant metabolites are produced when
high concentrations of oxygen are administered, such
as during oxygen therapy. Synergistic toxicity may
also be possible between high concentrations of oxy-
gen and drugs that can disrupt the normal oxidant/an-
tioxidant homeostasis. This appears to be the case with
bleomycin, cyclophosphamide and mitomycin (Klein
and Wilds, 1983; Stonich and Bressler, 1998).
Multidrug regimens
Although not clearly defined, the incidence and
severity of pulmonary toxicity may increase with
multi-drug regimens. Typically, these chemotherapy
regimens include bleomycin, mitomycin, cyclophos-
phamide, methotrexate or carmustine. It has not been
determined whether a single drug is the causative
agent or if the interaction of these antineoplastic drugs
results in enhanced toxicity (Stonich and Bressler,
1998). 
Miscellaneous
Other risk factors include smoking, pre-existing
lung disease, quantitative and qualitative differences
among individuals in activation and detoxification
pathways of drugs and chemicals, and also ethnicity, as
some ethnic groups may be at increased risk of
developing adverse pulmonary reactions to drugs
(Klein and Wilds, 1983; Camus et al., 2001; Foucher
and Camus, 2001).
DIAGNOSIS OF PULMONARY FIBROSIS IN
HUMAN AND VETERINARY PATIENTS
The earliest detection of pulmonary fibrosis may
be achieved through serial evaluations of pulmonary
function. However, the definitive diagnosis of cyto-
toxic drug induced pulmonary toxicity is difficult since
a detailed history of drug administration, in the ab-
sence of other situations that may lead to pulmonary
damage, is required. Patients receiving antineoplastic
therapy may have coincidental parenchymal and air-
way diseases, complicating the clinical picture.
Presentation may therefore be highly variable, contin-
gent upon individual drug regimen, incidental disease,
and coincidental pathology (Camus et al., 2001). 
Chest X-rays may show changes consistent with
progressive pulmonary fibrosis. Radiographic changes
typically appear as bilateral diffuse interstitial infil-
trates with patchy areas of consolidation. Alveolar and
interstitial reaction and pleural effusion may be found.
However, a patient may have a normal pulmonary X-
ray pattern, even when histological evidence of pul-
monary damage is present. Once radiographic signs
are noted, the process has often progressed irreversibly
(Camus et al., 2001).
Sequential carbon monoxide diffusion capacity
tests may indicate the presence of occult pulmonary
changes. During pulmonary function tests, typical ab-
normalities for a restrictive process are seen, with a re-
duced diffusion capacity, decreased total lung capacity,
and other ventilatory defects, while arterial blood
gases will show hypoxia with hypocapnia.
Pulmonary histo- or cytopathologic examination of
lung biopsies or tracheo-bronchial washes may reveal
endothelial cell damage, fibroblast proliferation, and
epithelial abnormalities (Camus et al., 2001).
Canine idiopathic pulmonary fibrosis is presented
as a chronic, progressively worsening lung disease
characterized by clinical signs of coughing, exercise
intolerance and variable dyspnoea and tachypnoea.
This disease is especially recognized in West Highland
White Terriers, although it has been diagnosed in other
breeds as well (Corcoran et al., 1999; Lobetti et al.,
2001; Webb and Armstrong, 2002; Norris et al., 2005).
The most prominent feature of chest auscultation are
inspiratory crackles. The main thoracic radiographic
change is a mild to severe, diffuse, interstitial pul-
monary pattern, with varying degrees of bronchial in-
volvement. Bronchoscopy sometimes reveals a mild
airway mucoid reaction. A definitive diagnosis can
only be made by histopathological examination of lung
tissue, which displays thickening of the alveolar septa,
interstitial fibrosis and pneumocyte hyperplasia (Cor-
coran et al., 1999; Lobetti et al., 2001; Webb and Arm-
strong, 2002). 
CASE REPORT
A 10-year old neutered female Basset Fauve de
Bretagne, with a body weight of 18 kg and a body sur-
face of 0.7 m2, was diagnosed with malignant lym-
phoma in De Ottenhorst Clinic on 9 September 2002.
On clinical examination, the dog was found to have
generally enlarged peripheral lymph nodes and pro-
fuse hepato- and splenomegaly. Definite diagnosis was
made through cytologic exams of fine-needle aspira-
tion biopsies of peripheral lymph nodes, liver and
spleen. No T – B cell differentiation on cytological
smears was available at that time and the owner de-
clined the option of histologic biopsies. Thoracic X-
rays showed no abnormalities. A complete blood count
(CBC) revealed an increased leukocyte count of 17.0
x 109/l (reference range 3.0–12.0 x 109/l), caused by a
neutrophil count of 14.3 x 109/l (reference range 3.6-
13 x 109/l), but without further abnormalities. Bio-
chemistry revealed no significant changes. The initial
treatment consisted of two L-asparaginase (Paronal,
Nycomed BV) injections (400 IU/kg) intramuscularly
with a one week interval. One week after the second L-
asparaginase injection, methylprednisolon (Moderin,
Pfizer Animal Health BV) was started orally in a dose
of 1 mg/kg twice daily and tapered over 4 weeks to an
alternating dose of 0.5 mg/kg twice daily. In combina-
tion with the start of methylprednisolon, vincristin
(Vincristin sulphate, Pharmachemie BV) was admini-
stered, in a dose of 0.65 mg/m2 intravenously. One
week after the vincristin infusion, cyclophosphamide
(Endoxan, Baxter BV) was given to the dog orally on
two consecutive days, in a dose of 125 mg/m2 per day,
and vincristin was repeated one week later. After the
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second dose of vincristin, the dog became lethargic.
At that time, the peripheral lymph nodes were still
moderately enlarged, and hepato- and splenomegaly
still existed. The owner declined further chemo-
therapy according to the planned protocol with a com-
bination of cyclophosphamide, doxorubicin, vincristin,
and prednisolon (short Wisconsin-Madison protocol).
The administration of methylprednisolon was stopped
as well. 
On 25 October 2002, therapy was started with lo-
mustine (CeCeNU, Medac) orally in a single dose of
50 mg, which equals 70 mg/m2, once every three
weeks. Amoxycillin-clavulanic acid (Synulox, Pfizer
Animal Health BV) therapy, to prevent septicemia
from lomustine induced myelosuppression, was started
two days after each lomustine administration, for eight
consecutive days. One week after the first lomustine
administration, all lymph node swelling and abdomi-
nal enlargement had disappeared. Immediately before
each dose of lomustine, a CBC was performed to de-
termine possible contra-indications for treatment due
to myelosuppression. 
In July 2003 a cumulative dose of 570 mg/m2 was
reached with the lymphoma still in complete remis-
sion. The lomustine dosing interval was increased to
once every five weeks and in September 2003 to once
every six weeks. Because of the potential increased
risk of renal toxicity, from July 2003 blood urea nitro-
gen and serum creatinine determination was performed
before each treatment, together with routine urine
examinations.
The final dose of lomustine was delivered to the
dog on 7 November 2003, and at that time the total
dose received was 720 mg lomustine, which equals a
cumulative dose of 1029 mg/m2. The urine examina-
tion at the end of October showed a significant pro-
teinuria with a normal blood creatinine level of 102
μmol/l (reference range 65-139 µmol/l). Therapy was
started with the angiotensin-converting-enzyme (ACE)
inhibitor ramipril (Vasotop, Intervet Nederland BV) in
a dose of 2.5mg once daily. The results of recent
studies suggest that when markedly proteinuric dogs
are treated with ACE inhibitors, a reduction in the
magnitude of proteinuria and renoprotective effects are
observed during treatment (Lees et al., 2005)
In January 2004 the dog started coughing and had
moderately labored breathing. Thoracic auscultation
revealed bilateral crackled lung sounds over the com-
plete thoracic wall. On routine biochemistry there was
an increase of the blood urea nitrogen 29.2 mmol/l
(reference range 2.3-9.1 mmol/l), creatinine 143
µmol/l (reference range 65-139 µmol/l) and alkaline
phosphatase 335 IU/l (reference range < 130 IU/l). On
thoracic radiographs, mild cardiomegaly was visible,
without any abnormal pulmonary pattern. On cardiac
ultrasound, the left atrial dimension was slightly en-
larged, without further abnormalities. The dog re-
ceived 100 mg enrofloxacin (Baytril, Bayer Animal
Health Division BV) orally once daily for 10 conse-
cutive days, which resulted in a partial remission of
the pulmonary signs. The owners stopped ramipril at
the end of January 2004, because in their opinion this
seemed to aggravate coughing. The coughing com-
pletely stopped.
In February and March 2004, the biochemistry was
regularly repeated. No worsening of kidney function
was noticed. Because of an increase in ALP, the bile
acids and urinary cortisol/creatinine ratio were moni-
tored. Bile acids 7 µmol/l (reference range < 10
µmol/l), ALP 232 IU/l (reference range < 73 IU/l),
ALP (65°) 183 IU/l (reference range < 73 IU/l) and
urinary cortisol/creatinine ratio of 1.3x106 made the
presence of liver damage or Cushing disease unlikely. 
In April 2004 coughing started again, together with a
dyspnea, and the dog was referred to the Clinic of
Small Animal Medicine, Faculty of Veterinary Medi-
cine, Ghent University in Belgium. On clinical
examination, moderate inspiratory and expiratory dys-
pnea was present and mild crackles could be heard at
the level of the nasal plane. The mucous membranes
were pink and the capillary refilling time was within
the normal range. Thoracic auscultation revealed mod-
erate crackles bilaterally. On cardiac auscultation, the
heart frequency was 120 beats per minute with a reg-
ular rhythm, and no murmur was present. On thoracic
radiographs, a severe diffuse interstitial to alveolar pat-
tern was found, mostly in the caudal lung lobes. Right-
sided cardiomegaly was present (Vertebral Heart Size
= 11 vertebrae). The pulmonic arteries towards the
right cranial lung lobe and both caudal lung lobes were
thickened and tortuous. The caudal aspect of the tra-
chea at the level of the heart base seemed mildly di-
lated. Echocardiography revealed a severe left
ventricular hypertrophy with a mildly decreased left
ventricular diameter. The left atrial diameter was at the
higher end of the normal range. The fractional shorte-
ning was 63%, which is high. The right ventricular
wall thickness could not clearly be discerned, but the
right ventricular diameter was at the higher end of the
normal range. The right atrium was mildly dilated. On
Doppler echocardiography, no regurgitations were
found and all blood flow velocities were within the
normal range. Systolic blood pressure, measured with
a Parks Doppler device, was 130 to 140 mmHg. Dif-
ferential diagnosis included chronic bronchitis, inter-
stitial pulmonary fibrosis and pulmonary infection.
Chronic bronchitis could be excluded because of the
absence of any pulmonary abnormalities on the
previous radiographs. Pulmonary infection was less
likely because of the atypical thoracic auscultation of
crackles and lack of explanation for the right sided car-
diomegaly. In conclusion, a most likely diagnosis of
diffuse interstitial pulmonary fibrosis with secondary
right heart enlargement was made. As the owners did
not agree to give oral corticosteroids, treatment was
started with theophyllin (Theolair, 3M) 125mg twice
daily, fluticason (Flixotide Glaxo-Smith-Kline) inhaler
50µg/dose 2 doses twice daily for 2 weeks followed
by 1 dose twice daily, and salbutamol (Ventolin,
Glaxo-Smith-Kline) inhaler 100µg/dose when needed.
As no significant heart failure was present, no cardiac
therapy was started at this moment. 
Despite treatment, the dog’s pulmonary signs wor-
sened and most of the time she was cyanotic. Eu-
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thanasia was performed at the owners’ request on 25
May 2004. The lymphoma was still in complete re-
mission at the time of death. Post-mortem examina-
tion was not permitted by the owners.
CONCLUSION
Survival time for an increasing number of veteri-
nary oncology patients is improving, for example
through a better knowledge of tumor subtype-specific
treatment protocols with cytotoxic drugs, and indivi-
dualized dose variations adapted to the response to
these drugs. In the near future, dogs treated with lo-
mustine-incorporated protocols will be part of this
group of long-time survivors. There are no indications
that the 1100 mg/m2 cumulative dose of lomustine that
leads to an increased risk of developing pulmonary fi-
brosis in human cancer patients will be different for
canine patients. Veterinary oncologists need to be
aware of this late side effect. In lomustine incorporated
treatment protocols, this maximum cumulative dose of
1100 mg/m2 should be reached at a point as late as pos-
sible in the treatment period of dogs with lomustine-
sensitive tumors, or else the therapy should be finished
before this cumulative dose has been reached. Since
the advanced pulmonary function tests used in human
medicine are not available on a routine basis for dogs,
accurate pulmonary auscultation and thoracic X-rays
for early detection of lung fibrosis are recommended
during the course of lomustine treatment.
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